{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03686332\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PERICLES","nct_id":"NCT03686332","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pericles-nct03686332. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PERICLES","arms":[{"description":"Patients in this group will concurrently be treated with locoregional radiotherapy and atezolizumab.\n\nDrug: Arm A: Atezolizumab and Radiotherapy\n\nAtezolizumab, 1200 mg, every 3 weeks, by IV infusion and receive 33 fractions of 1.5 or 1.8 Gy irradiation.","label":"Arm A: Atezolizumab and Radiotherapy","type":"OTHER"},{"description":"Atezolizumab, 1200 mg, every 3 weeks, by IV infusion.","label":"Arm B: Atezolizumab","type":"OTHER"}],"collaborators":["Hoffmann-La Roche"],"completion_date":{"date":"2023-09-15","type":"ACTUAL"},"conditions":["Penile Cancer"],"enrollment":{"count":32,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Arm A: Atezolizumab and Radiotherapy","otherNames":[],"type":"DRUG"},{"name":"Arm B: Atezolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2023-09-21","lead_sponsor":"The Netherlands Cancer Institute","official_title":"PERICLES (PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study)-a Phase 2 Study of Atezolizumab With or Without Radiotherapy in Penile Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-09-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival at 1 year.","timeFrame":"1 year"}],"references":[{"citation":"de Vries HM, Rafael TS, Gil-Jimenez A, de Feijter JM, Bekers E, van der Laan E, Lopez-Yurda M, Hooijberg E, Broeks A, Peters D, Seignette IM, Pos FJ, Horenblas S, van Rhijn BWG, Jordanova ES, Brouwer OR, Schaake E, van der Heijden MS. Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial. J Clin Oncol. 2023 Nov 1;41(31):4872-4880. doi: 10.1200/JCO.22.02894. Epub 2023 Jul 24.","pmid":"37487169","type":"DERIVED"}],"start_date":{"date":"2018-09-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study","url":"https://clinicaltrials.gov/study/NCT03686332"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pericles-nct03686332"}